CA
NZ
UK
AU
IND
US
Lumexa Imaging Holdings, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing a return to profitability versus a net loss in the prior-year comparable periods.
Grace Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 12, 2026, disclosing operational and regulatory developments related to its lead drug candidate GTx-104.
DPC Holdings PLC filed its Form 10-Q for the quarterly period ended September 27, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, reporting a third-quarter net income of $31.8 million alongside a nine-month net loss of $146.8 million.
Charlotte's Web Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $3.458 million for the third quarter and disclosing a significant mid-year conversion of its convertible debenture …
LASE Corp. filed a Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, reporting a net loss of $2,516,509 for the three months ended that date.
Artelo Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $1.768 million for the third quarter and a significant increase in cash and cash equivalents compared to …
Chenghe Acquisition III Co. filed its Form 10-Q for the quarter ended September 30, 2026, with the SEC on November 12, 2026, reporting quarterly net income of $975,037 and total assets of $131,521,148.
Imunon, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing condensed consolidated financial statements and management discussion for the period.
Vivani Medical, Inc. filed a Form 8-K on November 12, 2026, reporting top-line results from its SLIM-1 Phase 1 clinical trial of NPM-139, a semaglutide implant, alongside its third quarter 2026 financial results.
Patriot National Bancorp, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a return to quarterly net income after a year-to-date loss.
Please wait processing your request...